Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A Retrospective Observational Study of the Incidence and Associated Risk Factors of Skin Cancers in Renal Transplant Recipients in Canterbury, New Zealand.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 0135232 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-0960 (Electronic) Linking ISSN: 00048380 NLM ISO Abbreviation: Australas J Dermatol Subsets: MEDLINE
    • Publication Information:
      Publication: New South Wales : Wiley-Blackwell
      Original Publication: [Sydney] Australasian College of Dermatologists.
    • Subject Terms:
      Skin Neoplasms*/epidemiology ; Kidney Transplantation*/adverse effects ; Carcinoma, Basal Cell*/epidemiology ; Carcinoma, Squamous Cell*/epidemiology; Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Incidence ; New Zealand/epidemiology ; Risk Factors ; Adult ; Aged ; Age Factors ; Sex Factors ; Immunosuppressive Agents/adverse effects ; Cyclosporine/adverse effects
    • Abstract:
      Background: Skin cancer is a significant complication amongst renal transplant recipients, associated with substantial morbidity and mortality.
      Aim: This retrospective observational study aimed to assess the incidence and identify associated risk factors for skin cancers amongst renal transplant recipients in Canterbury, New Zealand.
      Methods: We retrospectively reviewed data from 177 renal transplant recipients who underwent transplantation between January 2004 and December 2015.
      Results: Amongst the patients, 32% developed skin cancers. The mean age of the study cohort is 57 years with a mean age at transplant of 47 years. A total of 315 histologically proven invasive skin cancers were recorded, with a squamous cell carcinoma (SCC) to basal cell carcinoma (BCC) ratio of 1.25:1. Forty-four patients had died by the study's conclusion, with metastatic skin cancer accounting for four deaths (9%). Non-melanoma skin cancers (NMSC) showed significant associations with older age and older age at transplant (p < 0.001). Male gender, skin phototype I-III, and ciclosporin exposure were also associated with increased NMSC risk (p < 0.05). The cumulative 10-year risk for NMSC amongst renal transplant recipients was estimated at 28.85% (95% CI = 28.77-28.91).
      Conclusion: This study confirms a high incidence of skin cancers amongst renal transplant recipients in Canterbury, New Zealand, consistent with international findings. Understanding the risk factors for skin cancer can aid in developing targeted strategies for prevention and management in transplant recipients.
      (© 2025 Australasian College of Dermatologists.)
    • References:
      S. Granata, G. Tessari, G. Stallone, et al., “Skin Cancer in Solid Organ Transplant Recipients: Still an Open Problem,” Frontiers in Medicine 10 (2023): 1189680.
      A. Pondicherry, R. Martin, I. Meredith, J. Rolfe, P. Emanuel, and M. Elwood, “The Burden of Non‐Melanoma Skin Cancers in Auckland, New Zealand,” Australasian Journal of Dermatology 59, no. 3 (2018): 210–213.
      M. J. Sneyd and A. Gray, Expected Non Melanoma Skin (Keratinocytic) Cancer Incidence in New Zealand for 2018 (Health Promotion Agency, 2018).
      D. O'Dea, The Costs of Skin Cancer to New Zealand (Cancer Society of New Zealand, 2009).
      M. Matinfar, S. Shahidi, and A. Feizi, “Incidence of Nonmelanoma Skin Cancer in Renal Transplant Recipients: A Systematic Review and Meta‐Analysis,” Journal of Research in Medical Sciences 23 (2018): 14.
      F. Xiang, R. Lucas, S. Hales, and R. Neale, “Incidence of Nonmelanoma Skin Cancer in Relation to Ambient UV Radiation in White Populations, 1978–2012: Empirical Relationships,” JAMA Dermatology 150, no. 10 (2014): 1063–1071.
      R. L. McKenzie, G. E. Bodeker, G. Scott, J. Slusser, and K. Lantz, “Geographical Differences in Erythemally‐Weighted UV Measured at Mid‐Latitude USDA Sites,” Photochemical & Photobiological Sciences 5 (2006): 343–352.
      K. A. Mackenzie, J. E. Wells, K. L. Lynn, et al., “First and Subsequent Nonmelanoma Skin Cancers: Incidence and Predictors in a Population of New Zealand Renal Transplant Recipients,” Nephrology, Dialysis, Transplantation 25, no. 1 (2010): 300–306.
      N. Cross, “Kidney Transplant Activity Report 2021,” https://www.tewhatuora.govt.nz/assets/About‐us/Who‐we‐are/Expert‐groups/National‐Renal‐Transplant‐Service/Papers‐and‐reports/kidney_transplant_activity_‐_nz_‐_2021_final.docx, accessed July 2024.
      H. M. Ramsay, A. A. Fryer, C. M. Hawley, A. G. Smith, D. L. Nicol, and P. N. Harden, “Non‐Melanoma Skin Cancer Risk in the Queensland Renal Transplant Population,” British Journal of Dermatology 147, no. 5 (2002): 950–956.
      R. McKenzie, “UV Radiation in the Melanoma Capital of the World: What Makes New Zealand So Different?” (2017), AIP Conference Proceedings, Feb 22 (1810, 1). AIP Publishing.
      R. P. Carroll, H. M. Ramsey, A. A. Fryer, et al., “Incidence and Prediction of Nonmelanoma Skin Cancer Post‐Renal Transplantation: A Prospective Study in Queensland, Australia,” American Journal of Kidney Diseases 41 (2003): 676–683.
      J. Bernat García, M. Morales Suárez‐Varela, J. J. Vilata, A. Marquina, L. Pallardó, and J. Crespo, “Risk Factors for Non‐Melanoma Skin Cancer in Kidney Transplant Patients in a Spanish Population in the Mediterranean Region,” Acta Dermato‐Venereologica 93 (2013): 422–427.
      A. Pinho, M. Gouveia, J. C. Cardoso, M. M. Xavier, R. Vieira, and R. Alves, “Non‐Melanoma Skin Cancer in Portuguese Kidney Transplant Recipients ‐ Incidence and Risk Factors,” Anais Brasileiros de Dermatologia 91, no. 4 (2016): 455–462.
      L. Naldi, A. B. Fortina, and S. Lovati, “Risk of Nonmelanoma Skin Cancer in Italian Organ Transplant Recipients: A Registry‐Based Study,” Transplantation 70 (2000): 1479–1484.
      P. N. Harden, A. A. Fryer, S. Reece, A. G. Smith, and H. M. Ramsay, “Annual Incidence and Predicted Risk of Nonmelanoma Skin Cancer in Renal Transplant Recipients,” Transplantation Proceedings 33 (2001): 1302–1304.
      S. Comeau, L. Jensen, S. M. Cockfield, M. Sapijaszko, and S. Gourishankar, “Non‐Melanoma Skin Cancer Incidence and Risk Factors After Kidney Transplantation: A Canadian Experience,” Transplantation 86, no. 4 (2008): 535–541.
      C. K. Park, K. Fung, P. C. Austin, et al., “Incidence and Risk Factors of Keratinocyte Carcinoma After First Solid Organ Transplant in Ontario, Canada,” JAMA Dermatology 155 (2019): 1041–1048.
      L. D. Crow, A. Jambusaria‐Pahlajani, C. L. Chung, et al., “Initial Skin Cancer Screening for Solid Organ Transplant Recipients in the United States: Delphi Method Development of Expert Consensus Guidelines,” Transplant International 32, no. 12 (2019): 1268–1276.
      G. L. Garrett, P. D. Blanc, J. Boscardin, et al., “Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States,” JAMA Dermatology 153, no. 3 (2017): 296–303.
      X. Hao, W. Lai, X. Xia, et al., “Skin Cancer Outcomes and Risk Factors in Renal Transplant Recipients: Analysis of Organ Procurement and Transplantation Network Data From 2000 to 2021,” Frontiers in Oncology 12 (2022): 1017498.
      K. Szumilas, A. Wilk, P. Wiśniewski, et al., “Current Status Regarding Immunosuppressive Treatment in Patients After Renal Transplantation,” International Journal of Molecular Sciences 24, no. 12 (2023): 10301.
      D. S. Rigel, J. K. Robinson, M. I. Ross, et al., eds., Cancer of the Skin, 2nd ed. (Elsevier, 2011).
      M. A. Kreher, M. M. B. Noland, S. Konda, M. I. Longo, and R. Valdes‐Rodriguez, “Risk of Melanoma and Nonmelanoma Skin Cancer With Immunosuppressants, Part I: Calcineurin Inhibitors, Thiopurines, IMDH Inhibitors, mTOR Inhibitors, and Corticosteroids,” Journal of the American Academy of Dermatology 88, no. 3 (2023): 521–530.
      F. J. Moloney, H. Comber, P. O'Lorcain, P. O'Kelly, P. J. Conlon, and G. M. Murphy, “A Population‐Based Study of Skin Cancer Incidence and Prevalence in Renal Transplant Recipients,” British Journal of Dermatology 154 (2006): 498–504.
      A. Cordaro, T. D. Dobbs, J. A. Gibson, S. Whitaker, and I. S. Whitaker, “Skin Cancer Screening in Organ Transplant Centres in the United Kingdom: A National Survey,” European Journal of Dermatology 30, no. 4 (2020): 372–376.
      A. Jambusaria‐Pahlajani, L. D. Crow, S. Lowenstein, et al., “Predicting Skin Cancer in Organ Transplant Recipients: Development of the SUNTRAC Screening Tool Using Data From a Multicenter Cohort Study,” Transplant International 32, no. 12 (2019): 1259–1267.
      Á. Gómez‐Tomás, J. N. Bouwes Bavinck, R. Genders, et al., “External Validation of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) in a Large European Solid Organ Transplant Recipient Cohort,” JAMA Dermatology 159, no. 1 (2023): 29–36, https://doi.org/10.1001/jamadermatol.2022.4820.
      L. J. H. Yoo, S. Bowe, C. Quigley, et al., “Assessing the Skin and UV Neoplasia Transplant Risk Assessment Calculator in an Irish Cohort of Thoracic Organ Transplant Recipients,” Clinical and Experimental Dermatology 49, no. 1 (2023): 68–70.
      Health New Zealand, “Cancer Web Tool: Rate of All Melanoma (C43) Cancer Registrations in 2017–2021 by District Health Board (DHB),” (2021), https://tewhatuora.shinyapps.io/cancer‐web‐tool, accessed 29 September 2024.
      E. Dahlke, C. A. Murray, J. Kitchen, et al., “Systematic Review of Melanoma Incidence and Prognosis in Solid Organ Transplant Recipients,” Transplantation Research 3 (2014): 1–8.
      A. C. Green and C. M. Olsen, “Increased Risk of Melanoma in Organ Transplant Recipients: Systematic Review and Meta‐Analysis of Cohort Studies,” Acta Dermato‐Venereologica 95, no. 8 (2015): 923–927.
      Y. Lee, P. Chao, C. Coomarasamy, and J. A. Mathy, “Epidemiology and Survival of Merkel Cell Carcinoma in New Zealand: A Population‐Based Study Between 2000 and 2015 With International Comparison,” Australasian Journal of Dermatology 60, no. 4 (2019): e284–e291.
      C. A. Clarke, H. A. Robbins, Z. Tatalovich, et al., “Risk of Merkel Cell Carcinoma After Solid Organ Transplantation,” Journal of the National Cancer Institute 107, no. 2 (2015): dju382.
      Stats NZ, “2023 Census Population Counts (by Ethnic Group, Age, and Māori Descent) and Dwelling Counts,” https://www.stats.govt.nz/information‐releases/2023‐census‐population‐counts‐by‐ethnic‐group‐age‐and‐maori‐descent‐and‐dwelling‐counts/, accessed July 2024.
      ANZDATA—Australia and New Zealand Dialysis and Transplant Registry, “ANZDATA 33rd Annual Report 2010 (Data to 2009),” https://www.anzdata.org.au/report/anzdata‐33rd‐annual‐report‐2010/, accessed July 2024.
      ANZDATA—Australia and New Zealand Dialysis and Transplant Registry, “ANZDATA 38th Annual Report 2016 (Data to 2015),” https://www.anzdata.org.au/report/anzdata‐39th‐annual‐report‐2016/, accessed July 2024.
    • Accession Number:
      0 (Immunosuppressive Agents)
      83HN0GTJ6D (Cyclosporine)
    • Publication Date:
      Date Created: 20250610 Date Completed: 20250909 Latest Revision: 20250910
    • Publication Date:
      20250911
    • Accession Number:
      10.1111/ajd.14538
    • Accession Number:
      40492672